Allergan posted a third-quarter loss of $671 million, compared with a profit of $179 million in the year-ago period, which was in line with analysts' expectations, due to charges related to a probe into the marketing of Botox and for the impairment of its Sanctura franchise. The drugmaker also reported that sales of pharmaceuticals for the three-month period were up 5 percent to $989 million, due in part to revenue growth for Botox, which recorded sales of $342 million, up 4 percent. Total revenue was $1.2 billion, which was in line with analyst forecasts.
Reference Articles
Allergan reports third quarter 2010 operating results - (Allergan)
Allergan earnings meet expectations - (Forexpros)
Charges weigh on Allergan earnings - (MarketWatch)
Allergan swings to 3Q loss on Botox deal; year view raised - (NASDAQ)
Allergan reports inline Q3 results - (SmarTrend)
*Published in "First Word"
No comments:
Post a Comment